Imported strongyloidiasis : Data from 1245 cases registered in the +REDIVI Spanish collaborative network (2009-2017)
Salvador, F. (Hospital Universitari Vall d'Hebron)
Treviño, Begoña (Hospital Universitari Vall d'Hebron)
Chamorro-Tojeiro, S. (Hospital Universitario Ramón y Cajal (Madrid))
Sánchez-Montalvá, Adrián (Hospital Universitari Vall d'Hebron)
Herrero-Martínez, J. M. (Hospital Universitario)
Rodríguez Guardado, Azucena (Hospital Universitario Central de Asturias)
Serre-Delcor, Núria (Hospital Universitari Vall d'Hebron)
Torrús-Tendero, Diego (Hospital General Universitario de Alicante (Alacant, País Valencià))
Goikoetxea, Josune (Hospital Universitario de Cruces (Barakaldo, País Basc))
Zubero, Z. (Hospital de Basurto)
Velasco, M. (Hospital Universitario Fundación Alcorcón)
Sulleiro Igual, Elena (Hospital Universitari Vall d'Hebron)
Molina Romero, Israel (Hospital Universitari Vall d'Hebron)
López-Vélez, R. (Hospital Universitario Ramón y Cajal (Madrid))
Pérez-Molina, Jose A. (Hospital Universitario Ramón y Cajal (Madrid))
Universitat Autònoma de Barcelona

Data:	2019
Resum:	Background Imported strongyloidiasis is increasingly being diagnosed in non-endemic areas. The aim of this study was to describe the epidemiological, clinical and microbiological characteristics of patients with imported strongyloidiasis in Spain. Methodology This is an observational retrospective study that included all patients diagnosed of strongyloidiasis registered in the +REDIVI Collaborative Network from 2009 to 2017. Demographic, epidemiological and clinical information was collected from the +REDIVI database, and extra information regarding microbiological techniques, treatment and follow-up was requested to participant centers. Findings Overall, 1245 cases were included. Most of them were immigrants (66. 9%), and South America was the most frequent area of origin. Detection of larvae in stool samples was observed in 21. 9% of the patients, and serological tests allowed making the diagnosis in the rest of the cases. Eosinophilia was present in 82. 2% of cases. Treatment with ivermectin (compared with albendazole) was the most strongly associated factor to achieve the cure (OR 2. 34). Conclusions Given the long latency of the infection and the risk of developing a severe presentation, screening of S. stercoralis infection should be mandatory in patients coming from or had traveling to endemic areas, especially in those with immunosuppressant conditions.
Drets:	Aquest document està subjecte a una llicència d'ús Creative Commons. Es permet la reproducció total o parcial, la distribució, la comunicació pública de l'obra i la creació d'obres derivades, fins i tot amb finalitats comercials, sempre i quan es reconegui l'autoria de l'obra original.
Llengua:	Anglès
Document:	Article ; recerca ; Versió publicada
Matèria:	Adolescent ; Adult ; Aged ; Aged, 80 and over ; Albendazole ; Animals ; Anthelmintics ; Child ; Child, Preschool ; Emigrants and Immigrants ; Eosinophilia ; Female ; Humans ; Infant ; Ivermectin ; Male ; Middle Aged ; Retrospective Studies ; South America ; Spain ; Strongyloides stercoralis ; Strongyloidiasis ; Travel ; Young Adult
Publicat a:	PLoS neglected tropical diseases, Vol. 13 Núm. 5 (may 2019) , p. e0007399, ISSN 1935-2735

DOI: 10.1371/journal.pntd.0007399
PMID: 31095570

14 p, 806.2 KB

El registre apareix a les col·leccions:
Articles > Articles de recerca
Articles > Articles publicats